


APGI BioResource – Patient Derived Cell Line Profiles

TKCC-22-LO

| | |
|---------------------------|--|
| PDCL Description: | TKCC-22-LO was derived from mouse xenografts initiated from a poorly differentiated adenocarcinoma taken from the pancreatic resection of an 84-year-old Caucasian female with cancer of the pancreas. |
| Mutation Status: | TKCC-22-LO has undergone whole genome sequencing and mutation status can be provided upon request. |
| Organism: | Human (<i>Homo sapiens</i>) |
| Tissue: | Pancreas, derived from primary tumour site. |
| Growth Properties: | Adherent |
| Morphology: | Epithelial. Small cells that form a monolayer at confluence. |
| Image: |  |
| Growth Medium: | Iscove's Modified Dulbecco's Medium supplemented with 20ng/mL human recombinant EGF, 12.5µg/mL human apo-transferrin, 0.2IU/mL Insulin, 0.5x MEM vitamin solution and 20% Foetal Calf Serum (FCS). |
| Cell line revival: | Quick-thaw the vial by gently agitating in a 37°C water bath (approx. 2 mins). A centrifugation step to remove the cryoprotectant medium after thawing is necessary for this cell line. |

| | |
|--|--|
| <p>Subculturing Procedure:</p> | <p><i>Medium Renewal:</i> Every 2-3 days.</p> <p><i>Subcultivation Ratio:</i> 1:2</p> <p><i>Seeding density:</i> 1.5×10^4 cells/cm². Harvest the cells at 37°C using PBS-EDTA (PBS + 0.25% glucose + 96 μM EDTA) for 20 mins followed by 0.05% Trypsin/EDTA for a further 5 minutes. Flasks will require passaging twice weekly at this seeding density. For a more detailed culturing protocol please see additional documents.</p> <p><i>Culture Conditions:</i> Incubate the culture at 37°C with 5% CO₂ and 5% O₂.</p> <p><i>Cryoprotectant Medium:</i> 50% FCS + 40% culture medium + 10% DMSO.</p> |
| <p>Handling Procedure for Frozen Cells:</p> | <p>Upon receipt, frozen vials should be transferred directly into liquid nitrogen storage (if not used immediately). Prolonged storage at -80°C may result in loss of viability.</p> |
| <p>Availability:</p> | <p>This cell line is available exclusively from the Garvan Institute of Medical Research, Sydney, Australia. If you are interested in obtaining this cell line, please submit an APGI BioResource Application as per the instructions on the APGI website (www.pancreaticcancer.net.au/bioresource-pdcls/).</p> |
| <p>Depositor:</p> | <p>Dr Marina Pajic (Personalised Cancer Therapeutics Group, Garvan Institute) on behalf of the APGI</p> |
| <p>Acknowledgements:</p> | <p>Please acknowledge the APGI and The Garvan Institute of Medical Research in all publications and patent applications that make reference to this cell line.</p> |
| <p>Use Restrictions:</p> | <p>These cells are distributed for research purposes only and are not to be re-distributed to third parties.</p> |
| <p>Additional Information:</p> | <p>Please refer to www.pancreaticcancer.net.au/bioresource-pdcls/ for more detailed subculture, reagent preparation, freezing and reviving TKCC cell line methodology.</p> |